#USA #Philadelphia #Penn Dental Medicine #ACE inhibitors #ACE2 enzyme

Penn Dental Medicine Study and Its Surprising Findings

Hypertension, commonly known as high blood pressure, is a widespread condition affecting over a billion individuals worldwide. Many patients utilize angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs), both of which play crucial roles in managing this medical concern. However, research from Penn Dental Medicine has recently uncovered unexpected interactions between these common medications and a previously underutilized enzyme, ACE2.

Understanding Hypertension and Current Treatments

Hypertension is regulated through the renin-angiotensin system (RAS), which involves a series of enzymatic reactions that lead to blood pressure regulation. Renin, the first enzyme released in this pathway, converts angiotensinogen to angiotensin I. Subsequently, ACE transforms angiotensin I into angiotensin II—a potent vasoconstrictor that increases blood pressure. By inhibiting various steps in this process, ACE inhibitors and ARBs effectively lower blood pressure. Yet, despite these treatments, many patients continue to struggle with uncontrolled hypertension, suggesting a need for further therapeutic options.

In light of this ongoing challenge, researchers at Penn Dental Medicine assessed the potential benefits of introducing oral ACE2 into the hypertensive treatment regimen. Previous studies have shown that ACE2, when delivered via injection, can yield positive effects in managing RAS-associated diseases. This led the team to explore whether oral ACE2 could enhance the efficacy of standard hypertension medications.

Surprising Discoveries During the Study

Led by Henry Daniell, W.D. Miller Professor at Penn Dental Medicine, the study revealed unexpected results. Upon administering ACE2 to canines suffering from myxomatous mitral valve disease—who were also being treated with standard ACE inhibitors or ARBs—the researchers made two startling observations. First, they found that ACE inhibitors inadvertently inhibited the activity of the ACE2 enzyme they were administering. This unexpected interaction posed a significant concern, as it could interfere with the intended blood pressure-lowering effects of the treatment.

Secondly, dogs treated with ARBs showed an increase in angiotensin II levels, contradicting the goal of reducing these levels to manage hypertension effectively. Daniell noted that these findings can complicate the existing treatment landscape and highlight the need for tailored therapeutic strategies.

The Road Ahead for Research

Despite these hurdles, the research team discovered that not all ACE inhibitors have the same impact on ACE2 activity. This raises an intriguing avenue for further exploration. Next, the study aims to focus on the behavior of lisinopril, as it appeared to have a less inhibitive effect on ACE2.

Daniell envisions using the plant-encapsulation system employed in this research for future human studies. By closely examining the potential benefits of ACE2 in treating hypertension, the team hopes to contribute invaluable insights toward developing more effective strategies for managing this prevalent condition.

Concluding Thoughts

The Penn Dental Medicine study sheds light on the complexity of treating hypertension and the potential for innovative solutions in managing this global health challenge. As researchers continue to refine our understanding of how various medications interact within the body, there is hope for improved outcomes for the millions affected by high blood pressure. With a commitment to advancing knowledge in this field, researchers like Daniell pave the way for better health management practices worldwide.